Compare Hershey Co (HSY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Novavax Inc — how do they compare? Hershey Co trades at $162.74 (market cap $32.66B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Hershey Co is far larger — about 17.9× Novavax Inc's market cap, and Hershey Co pays a 3.57% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Novavax Inc for 59 Days on average.
| HSY | NVAX | |
|---|---|---|
Market Cap | $32.66B | $1.82B |
Volume | 1,578,237 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $12.75 |
52-Week Low | $157.61 | $6.22 |
Typical Hold Time | 135 Days | 59 Days |
Enterprise Value | $37.79B | $1.39B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.54, up 1.37% with a bearish technical signal despite beating earnings expectations for three consecutive quarters. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though 2025 net income declined significantly. Recent news highlights dividend resumption and international leadership changes while analysts maintain a cautious stance with 65.72% hold ratings.
HSY presents a mixed outlook with solid fundamentals offset by near-term challenges. The 26% upside to consensus price target of $204.62 offers potential, but cocoa cost pressures and technical bearishness warrant caution. Dividend investors may find value given the recent payout resumption, though margin compression remains a key monitorable.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
